 Home > Active Ingredient News > Antitumor Therapy > European Radiology: Evaluation of left atrial remodeling in patients with breast cancer treated with adjuvant trastuzumab by CMRI

European Radiology: Evaluation of left atrial remodeling in patients with breast cancer treated with adjuvant trastuzumab by CMRI

 Last Update: 2022-04-15
 Source: Internet
 Author: User

Tags

used pax 2

amlodipine heart failure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer , anti -HER2 therapies such as trastuzumab have greatly improved survival in both adjuvant and metastatic settings .

Cardiac magnetic resonance imaging (CMR) is the gold standard technique for quantitative assessment of cardiac chambers , with higher reproducibility and spatial resolution than echocardiography

In this prospective, two-center longitudinal study, 41 women with HER2-positive breast cancer received 12 months of adjuvant trastuzumab in addition to standard chemotherapy

Among 41 women (mean age, 52 ± 11 [SD] years; 56% received anthracyclines), one patient developed trastuzumab-induced cardiotoxicity (TIC), which resulted in trastuzumab interrupted for one cycle

In this prospective cohort study of trastuzumab-treated breast cancer patients, there was a small but significant subclinical decrease in LAEF and a modest increase in LAmin after initiation of treatment , which returned to baseline 6 months after treatment was discontinued

Original source :

Flora Huang , Christine Brezden-Masley , Kelvin KW Chan , et al .

Flora Huang Christine Brezden-Masley Kelvin KW Chan , et al Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab 10.
1007/s00330-021-08466-9 10.
1007/s00330-021-08466-9

at this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.